GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. is an American medical technology company that designs, manufactures, and services diagnostic imaging equipment, ultrasound systems, patient monitoring devices, and pharmaceutical diagnostic agents, generating $20.6 billion in revenue in fiscal 2025. The company was spun out of General Electric in January 2023 after more than a century inside the industrial conglomerate, and today stands as one of the largest pure-play imaging and diagnostics companies in the world, with roughly 54,000 employees, operations in over 160 countries, and an installed base of more than four million imaging units.

This is a story about an incumbent medical-technology franchise executing one of the most ambitious innovation cycles in its history at the same moment that input-cost inflation, China policy headwinds, and the normal lumpiness of capital equipment demand are testing its operational discipline. The company sits at the intersection of two durable secular forces — an aging global population that needs more diagnostic imaging and a pharmaceutical industry that increasingly depends on imaging to select patients and measure outcomes — and has constructed a portfolio that captures both the equipment and the consumable. But the stock trades at roughly 11.6x trailing EBITDA, a discount to peers that reflects genuine uncertainty about whether the new-product cycle can overcome the tariff and inflation overhang that has compressed margins since the spin.

The file turns on a single question: whether the wave of innovation that GE HealthCare has been building toward — Photon Counting CT, a novel cardiovascular PET tracer, a gadolinium-free MRI contrast agent, and a cloud-connected imaging SaaS platform — arrives in time and with enough commercial force to re-accelerate revenue growth and restore the margin trajectory that tariffs interrupted.